Natriuretic Peptides (ANP/BNP)
Cardiac Hormone PeptideapprovedAlso known as: ANP, BNP, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, NT-proBNP, Nesiritide, CNP
A family of cardiac hormones that regulate blood pressure, fluid balance, and cardiac function — used clinically for heart failure diagnosis and treatment, and increasingly studied for cardioprotective benefits.
Overview
Natriuretic peptides are a family of structurally related peptide hormones with critical roles in cardiovascular homeostasis. ANP (Atrial Natriuretic Peptide, 28 amino acids) is released from atrial cardiomyocytes in response to atrial stretch; BNP (Brain Natriuretic Peptide, 32 amino acids) is released from ventricular cardiomyocytes during volume overload and wall stress; CNP (C-type Natriuretic Peptide) is produced by endothelial cells. Together, they counteract the renin-angiotensin-aldosterone system (RAAS) to reduce blood pressure, promote sodium excretion (natriuresis), and protect the heart from pathological remodeling. BNP and NT-proBNP are used as diagnostic biomarkers for heart failure. Nesiritide (recombinant BNP) is FDA-approved for acute decompensated heart failure. In the longevity community, natriuretic peptides are of interest for their cardioprotective and anti-fibrotic properties.
Mechanism of Action
Natriuretic peptides signal through guanylyl cyclase receptors (NPR-A, NPR-B): (1) Binding activates intracellular cGMP production, promoting vasodilation; (2) Inhibit sodium reabsorption in renal collecting ducts (natriuresis); (3) Suppress renin secretion and aldosterone production; (4) Reduce cardiac preload and afterload; (5) Inhibit sympathetic nervous system activation; (6) Anti-fibrotic effects — suppress cardiac fibroblast proliferation and collagen production; (7) Anti-hypertrophic — prevent pathological cardiac remodeling; (8) Promote lipolysis and fat oxidation through NPR-A signaling in adipose tissue.
Molecular Formula
ANP: C127H203N45O39S3; BNP: C143H244N50O42S3
Molecular Weight
ANP: 3080.5 g/mol; BNP: 3464.0 g/mol
Sequence
ANP: 28-amino acid ring structure with disulfide bond; BNP: 32-amino acid ring structure
Dosage Protocols
Dose Range
0.01 mcg/kg/min – 0.03 mcg/kg/min
Frequency
Continuous IV infusion
Route
intravenous
Cycle Length
24-48 hours (acute treatment)
Hospital use only. Nesiritide is administered as a continuous IV drip with hemodynamic monitoring. Not for self-administration. Optional 2 mcg/kg bolus before infusion.
Source: FDA prescribing information (Natrecor)
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
IV infusion vials
Last Updated
2026-02
Nesiritide (Natrecor) for acute heart failure. Hospital-administered. Not available for outpatient use. Clinical pricing only.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Hypotension | severe |
| Headache | mild |
| Nausea | mild |
| Renal impairment | moderate |
Pros & Cons
FDA-approved therapy with established clinical utility in acute heart failure
Natural cardiac hormones with well-understood physiology
Anti-fibrotic and anti-hypertrophic effects protect against cardiac remodeling
Diagnostic biomarkers (BNP/NT-proBNP) enable monitoring of cardiac health
Clinical use requires hospitalization and continuous monitoring
Significant hypotension risk limits therapeutic utility
Short half-life requires continuous infusion
Not practical for biohacking or self-administration
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Nesiritide (recombinant BNP) is FDA-approved for acute heart failure. ANP and CNP analogs are in clinical development. Used clinically under medical supervision. BNP/NT-proBNP widely used as diagnostic blood tests.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.